HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Granules India rises on securing ANDA approval for Bupropion Hydrochloride Extended-Release Tablets
Oct-18-2024

Granules India is currently trading at Rs. 596.95, up by 3.70 points or 0.62% from its previous closing of Rs. 593.25 on the BSE.

The scrip opened at Rs. 591.20 and has touched a high and low of Rs. 601.50 and Rs. 578.85 respectively. So far 34024 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 724.55 on 02-Sep-2024 and a 52 week low of Rs. 319.20 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 613.45 and Rs. 578.85 respectively. The current market cap of the company is Rs. 14464.56 crore.

The promoters holding in the company stood at 38.87%, while Institutions and Non-Institutions held 34.34% and 26.80% respectively.

Granules India has received an approval from the U.S. Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) 100 mg, 150 mg, and 200 mg filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company.

Bupropion Hydrochloride Extended-Release Tablets USP (SR) are bioequivalent and therapeutically equivalent to Wellbutrin SR Sustained-Release Tablets, 100 mg, 150 mg, and 200 mg, by GlaxoSmithKline LLC. This is a widely prescribed medication for the treatment of major depressive disorder and for the prevention of seasonal affective disorder. Granules now has a total of 67 ANDA approvals from the USFDA.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


  RELATED NEWS >>